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Microfibril-associated glycoprotein-1 (MAGP-1) is 
a component of vertebrate extracellular matrix 
(ECM) microfibrils that, together with the fibrillins, 
contributes to microfibril function. Many of the 
phenotypes associated with MAGP-1 gene 
inactivation are consistent with dysregulation of the 
transforming growth factor β (TGFβ)/bone 
morphogenetic protein (BMP) signaling system. 
We have previously shown that full-length MAGP-
1 binds active TGFβ-1 and some BMPs. The work 
presented here further defines the growth factor–
binding domain of MAGP-1. Using recombinant 
domains and synthetic peptides, along with surface 
plasmon resonance analysis to measure the kinetics 
of the MAGP-1–TGFβ-1 interaction, we localized 
the TGFβ- and BMP-binding site in MAGP-1 to a 
19-amino-acid-long, highly acidic sequence near 
the N terminus. This domain was specific for 
binding active, but not latent, TGFβ1. Growth 
factor activity experiments revealed that TGFβ-1 
retains signaling activity when complexed with 
MAGP-1. Furthermore, when bound to fibrillin, 
MAGP-1 retained the ability to interact with TGFβ-
1, and active TGFβ-1 did not bind fibrillin in the 
absence of MAGP-1. The absence of MAGP was 
sufficient to raise the amount of total TGFβ stored 
in the ECM of cultured cells, suggesting that the 
MAGPs compete with the TGFβ large latent 
complex for binding to microfibrils. Together, these 
results indicate that MAGP-1 plays an active role in 
TGFβ signaling in the ECM.  
 
INTRODUCTION 
The extracellular matrix (ECM) is a composite 
biomaterial that contains informational signals 
that influence cell phenotypes.  The changing 
composition of the ECM during development and 
tissue repair provides necessary feedback signals 
used by cells to build functional tissues.  
Information from the ECM is transmitted to cells 
through direct interaction with specific receptors 
(e.g., integrins), through mechanical signals that 
reflect the material properties of the ECM and 
cellular microenvironment, and through 
regulation of growth factor accessibility and 
signaling. Many ECM proteins bind growth 
factors and regulate their activity by providing a 
pericellular substrate for presenting growth 
factors to specific receptors on cells or by 
sequestering active and latent forms away from 
the cell for later utilization (1). Growth factors 
bind to discrete domains and motifs in ECM 
proteins, and there is remarkable specificity to 
these binding interactions. As the ECM changes 
during development, so does the repertoire of 
ECM-associated growth factors that influence 
cell phenotypes.  
 The microfibril is an extracellular matrix 
structure made up of fibrillin as the core unit. 
Fibrillin appeared early in evolution and, over 
time, developed both structural and signaling 
functions (2).  Fibrillin monomers assemble into 
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fibers of 12-15 nm diameter that provide strength 
to tissues by forming fiber bundles.  An example 
includes the ciliary zonule in the eye, where 
microfibrils form the suspensory ligaments that 
support the lens (3,4). Microfibrils are also an 
important structural component of primitive 
vertebrate and invertebrate arteries where they 
provide a degree of elastic recoil (5-7).  
 Another key function of microfibrils is 
modulation of growth factor signaling through 
fibrillin interactions with the latent TGFβ binding 
proteins (LTBPs). LTBPs covalently bind the 
small latent complex of TGFβ to form the large 
latent TGFβ complex (TGFβ-LLC), which binds 
to fibrillin (8,9).  By sequestering latent TGFβ in 
the matrix, microfibrils indirectly regulate TGFβ 
signaling by providing a store of inactive growth 
factor that can be utilized through activation by 
proteolysis or by mechanical strain (10).   
 With the arrival of vertebrates in evolution, 
new proteins appeared that interact with fibrillin 
and modify microfibrillar function.  These 
include elastin and microfibril-associated 
glycoprotein-1 and -2 (MAGP-1 and MAGP-2).  
Elastic fiber formation requires microfibrils (11) 
and, because MAGP-1 can bind both tropoelastin 
(12,13) and fibrillin (14), the MAGPs were 
initially thought to promote the tropoelastin-
microfibril interaction necessary for elastin 
assembly.  However, inactivation of the genes for 
MAGP-1 and MAGP-2 in mice did not affect 
elastic fiber formation. Instead, mice lacking 
these proteins had abnormalities in bone, fat, 
hematopoiesis, and wound healing that were 
associated with abnormal TGFβ signaling (15-
17). We have previously documented a direct 
binding interaction between TGFβ family growth 
factors and the MAGPs (18), but the sequence 
within MAGP that mediates this interaction was 
unknown. In this report, we localize the growth 
factor-binding domain in MAGP-1 to a sequence 
near the protein’s amino terminus and address the 




Characterization of recombinant purified full-
length MAGP-1 and MAGP-1 fragments. 
Full-length mouse MAGP-1 (exons 3-9) was 
expressed in E-coli along with a series of N-
terminal truncation mutants containing a N-
terminal 6-His-tag. The truncations were based 
on the exon structure of the gene encoding the 
mature molecule shown in Fig 1A (the protein 
sequence for mouse MAGP-1 can be found in 
supporting information Fig S1). The gene for 
MAGP-1 contains nine exons, but only seven 
encode the secreted full-length protein.  Exon 1 is 
untranslated, and exon 2 encodes the majority of 
the signal peptide, which is absent from the 
mature molecule.  After confirming the correct 
sequence for each construct by DNA sequence 
analysis, the constructs were expressed, and the 
proteins purified.  The results of the purification 
are shown in Fig 1B.  The full-length protein has 
a predicted mass of 20.6 kDa, but by SDS-PAGE 
analysis migrates ~36 kDa. Similarly, the 
bacterially expressed domain 3-4 construct has a 
predicted mass of ~7.5 kDa but runs at 
approximately 16 kDa.  Purified domain 4-9 runs 
slightly higher than expected (19 kDa compared 
to the predicted 17.5 kDa), and the domain 5-9 
protein runs true to the predicted mass of ~16 
kDa.  Because the MAGP-1 protein and 
fragments are expressed in bacteria, the irregular 
migration is not due to post-translational 
modifications.  Anomalous migration of full-
length MAGP-1 on SDS-PAGE has been 
described (19).  Our results suggest that the 
sequence within domains 3-4 is responsible for 
this irregular behavior.  
TGFβ binding to MAGP-1 fragments 
Our goal in this study was to localize the region 
of MAGP-1 that interacts with TGFβ growth 
factors.  To this end, we performed a set of 
surface plasmon resonance (SPR) experiments 
where purified TGFβ-1 was injected over 
immobilized full-length MAGP-1 or over the 
purified truncation fragments coupled to CM-5 
sensor chips.  Fig 2A shows binding isotherms 
for soluble TGFβ-1 interacting with immobilized 
full-length MAGP-1 in the SPR-based assay.  The 
affinity constant calculated using 1:1 Langmuir 
binding was 15nM.  When tested for binding to 
the MAGP-1 fragments, TGFβ-1 bound the 
domain 3-4 coupled sensor chip with a slightly 
higher affinity than the full-length protein, as 
seen in Fig 2B.  The affinity constant calculated 
using 1:1 Langmuir binding was 3nM.  Binding 
of TGFβ-1 to domain 4-9 showed substantially 











lower affinity (190nM), and there was no TGFβ-
1 binding to a chip coated with domain 5-9 (Fig 
2C and 2D, respectively). These results suggest 
that the primary binding site for TGFβ-1 is 
located in domain 4 of MAGP-1 with an affinity 
contribution from domain 3. 
TGFβ binds to a 19-residue peptide sequence 
spanning domains 3 and 4 
Fine mapping of the MAGP-1binding sequence 
for TGFβ-1 was done using overlapping synthetic 
peptides that spanned the sequence encoded by 
exons 3 and 4.  Each peptide was purified by 
high-pressure liquid chromatography, and the 
sequence confirmed by mass spectrometry (data 
not shown). Surprisingly, TGFβ-1 failed to bind 
to a CM-5 sensor chip coated with a synthetic 
peptide made from the sequence of domain 3-4. 
The sequence was the same as the bacterially 
expressed domain 3-4 peptide except for an N-
terminal 6-His-tag on the bacterially expressed 
protein. The 6-His-tag itself was not an active 
binding sequence since the expressed peptide 5-9 
did not bind TGFβ-1 even though it also had a 6-
His-tag at the amino-terminus  
 Although unable to bind TGFβ-1 when 
bound to a solid substrate, domain 3-4 synthetic 
peptide (p1-35) did inhibit binding of TGFβ-1 to 
a full-length MAGP-1-coated sensor chip, 
thereby establishing its activity (supporting 
information Fig S2A). Therefore, for subsequent 
mapping studies, we used equilibrium titration 
experiments to assess the inhibitory activity of a 
series of peptides summarized in Fig 3A.  The 
peptide based on the first 18 residues of domain 
3 (p1-18) showed no inhibitory activity.  A 
peptide derived from residues 22-36 (p22-36), 
and a domain 4 peptide (p26-35) both failed to 
inhibit TGFβ-1 binding to full-length MAGP-1 
(the inhibitory curve for peptide p22-36 is shown 
in supporting information Fig S2B as 
representative of no binding inhibition).  A 
peptide with residues 12-37 (not shown) and a 
smaller peptide spanning residues 17-35 (p17-
35), were both inhibitory.   
 A detailed investigation into the dose-
response of the smallest peptide with inhibitory 
activity (p17-35) is shown in Fig 3B.  There is a 
dose-dependent decrease in TGFβ-1 binding to 
full-length MAGP-1, with half-maximal 
inhibition at approximately 30µM p17-35 (Fig 
3C).  These results are consistent with data from 
studies with recombinant MAGP-1 fragments 
and show that the TGFβ-1 binding activity of 
MAGP-1 is defined by a 19 amino acid sequence 
in domains 3 and 4.  A control peptide with 
conformational restraints containing four proline 
residues (p17-35pro) failed to inhibit TGFβ-1 
binding to full-length MAGP-1 (Fig 3D).  
 Secondary structure predictions for the 
MAGP-1 p17-35 peptide indicated that the 
sequence does not have extensive secondary 
structure elements, with most residues predicted 
to be a random coil (data not shown).  IUPred 
results predicted a high degree of disorder from 
the primary sequence.  PEP-FOLD models 
tended to be elongated or compact coils with little 
secondary structure.  This region of the MAGP-1 
protein is likely intrinsically disordered and 
cannot adopt an ordered state without binding to 
a binding partner such as such as a member of the 
TGFβ superfamily. 
MAGP-1 binds active, but not latent, TGFβ-1 
TGFβ is produced as a disulfide-linked 
homodimer that is inactive due to the presence of 
the N-terminal latency-associated peptide. This 
small latent TGFβ complex (SLC) is usually 
associated with LTBP1 to produce the large latent 
TGFβ complex (LLC), which is covalently bound 
to fibrillin-containing microfibrils in the ECM 
(9).  To determine if MAGP-1 interacts with 
latent TGFβ-1, we injected the small latent 
complex form of TGFβ-1 over a sensor chip 
coated with full-length MAGP-1.  As shown in 
Fig 4, latent TGFβ-1 at 15nM failed to bind to the 
full-length protein. However, after acid activation 
for 15 minutes, the same latent TGFβ-1 
preparation showed a robust interaction with 
MAGP-1.   
Neither MAGP-1 nor p17-35 inhibits TGFβ-1 
signaling.    
To investigate whether TGFβ-1 can still interact 
with its cellular receptor when complexed with 
MAGP-1, we pre-mixed MAGP-1 or MAGP-1 
fragments with active TGFβ-1 and then added the 
complex to the reporter cell line MFB-F11. MFB-
F11 cells are embryonic fibroblasts from Tgfb1-/- 
embryos stably transfected with a reporter 
plasmid consisting of TGFβ responsive Smad-
binding elements coupled to a secreted alkaline 











phosphatase reporter gene (20). The secreted 
alkaline phosphatase can be detected with a 
chemiluminescent substrate and provides a 
sensitive assay for TGFβ activity.  We found that 
full-length MAGP-1 does not influence TGFβ-1-
stimulated alkaline phosphatase release from the 
MFB-F11 reporter cells when tested over a wide 
range of MAGP-1 concentrations (Fig 5A).  
Similarly, MAGP-1 peptide p17-35 that blocks 
binding of TGFβ-1 to full-length MAGP-1, 
presumably by binding to the MAGP-1 binding 
site on the growth factor, does not affect the 
signaling potential of TGFβ-1 (Fig 5B).   
 The effects of MAGP-1 on TGFβ activity 
were also investigated by assessing changes in 
the SMAD signaling pathway in RFL-6 cells. In 
agreement with the MFB-F11 reporter cell assay, 
pre-incubating TGFβ-1 with soluble MAGP-1 
did not inhibit RFL-6 TGFβ-1-stimulated Smad-
2 phosphorylation (Fig 5C).  Fig 5D shows that 
Smad-2 phosphorylation is TGFβ dose dependent 
in RFL-6 cells with minimal pSmad2 detected in 
the absence of TGFβ.   
Predicted MAGP-1 binding site on TGFβ  
Molecular docking experiments consistently 
placed the MAGP-1 peptide p17-35 in contact 
with the finger region of TGFβ-1 (Fig 6).  The 
peptide prefers to dock near a cluster of positive 
residues in this region (R94, K95, and K97) that 
are solvent-exposed and, hence, in a position to 
attract and bind the negatively charged MAGP-1 
peptide.  The MAGP-1 peptide remains a highly 
flexible coil even when bound, suggesting that 
binding occurs through a promiscuous charge-
charge interaction between the highly positive 
region of TGFβ-1 and the negative residues of 
MAGP-1.  The critical positively charged 
residues are inaccessible in the inactive TGFβ-
LAP complex, due to the presence of the latency 
lasso in the straight-jacket region of the large 
latency-associated complex (21).  Masking of the 
MAGP-1 binding site by the latency peptide 
explains why MAGP-1 binds active TGFβ but not 
the small latent complex.   
MAGP forms a ternary complex with fibrillin-
2 and TGFβ-1.  
Fibrillin interacts with LTBP1 to covalently 
anchor the TGFβ large latent complex into the 
ECM (9,22).  Whether active TGFβ-1 can bind to 
fibrillin is unclear.  To explore a possible binding 
interaction between the two proteins, we injected 
50nM of active TGFβ-1 over full-length fibrillin-
2 immobilized on an SPR chip. Fibrillin-2 was 
purified from a baculoviral expression system 
and showed a single band by SDS-PAGE 
(supporting information Fig S3). Fig 7A shows 
that no significant interaction was detected 
between TGFβ-1 and fibrillin-2.  Soluble MAGP-
1, however, bound tightly to fibrillin-2 with an 
apparent affinity constant of 100pM (Fig 7B). 
The binding curve fits 1:1 Langmuir binding with 
a noticeable slow dissociation rate of -2.64 x 104s-
1 and a half-life of 2600 seconds.  We took 
advantage of this slow release rate to follow 
MAGP-1 injection onto the fibrillin-2 chip with 
50nM of TGFβ-1 and found robust binding of the 
growth factor to the fibrillin-2-MAGP-1 complex 
(Fig 7C).  That MAGP-1 mediated the interaction 
was established by inhibiting TGFβ binding with 
the active MAGP-1 peptide p17-35 (Fig 7C).  
The binding of TGFβ-1 to the MAGP-1-fibrillin-
2 complex showed similar binding kinetics to 
TGFβ-1 binding directly to a MAGP-1-coated 
chip (compare the top curve in Fig 3B to Fig 7C). 
 
BMP-2 binds to the same MAGP-1 sequence 
as TGFβ. 
Our previous studies found that MAGP-1 bound 
to BMP-7 with an affinity approximately equal to 
TGFβ (18).  To determine whether other BMP-
family members interact with MAGP-1, we 
performed SPR experiments with BMP-2.  Fig 
8A shows BMP-2 binding to MAGP-1 with an 
affinity of 25nM. The binding was inhibited by 
the active MAGP-1 peptide p17-35, suggesting 
that TGFβs and BMPs recognize the same 
sequence on the MAGP-1 protein.  The control 
peptide p17-35pro (Fig 8B) and the N-terminal 
peptide p1-18 (not shown) both failed to inhibit 
BMP-2 binding to full-length MAGP-1.  We were 
unable to determine if BMP-2 could form a 
ternary complex with fibrillin-2 and MAGP-1 
because BMP-2 bound directly to fibrillin-2 with 
an affinity of 8nM (supporting information Fig 
S4). 
Matrix devoid of MAGPs has higher TGFβ 
incorporation 
The majority of TGFβ in the ECM is in the form 











of the large latent complex bound to fibrillin.  
MAGP-1 and the large latent complex bind to the 
same region of fibrillin (23), suggesting a 
possible competition between the two proteins for 
binding to microfibrils.  To determine if the 
absence of MAGP allows for more latent 
complex to accrue in the ECM, we compared total 
and active TGFβ levels in cultures of fibroblasts 
from WT and MAGP knockout cells.  Because 
MAGP-2 can also bind TGFβ (16) and might 
compensate in the absence of MAGP-1, we 
evaluated TGFβ levels in MAGP-1 and MAGP-2 
knockout MEFs as well as MEFS from MAGP-
1;MAGP-2 double knockout mice. After 14 days 
of culture, there was 2-3 times more total (latent 
plus active) TGFβ activity in acid-activated cell-
ECM extracts of all MAGP knockout cells 
compared to WT (Fig 9 black bars). TGFβ 
activity detected without acid activation 
(indicative of active TGFβ) was also increased in 
the single knockout cell lines but was 
significantly lower in the double knockout MEFS 
(Fig 9 gray bars).  Quantitative PCR confirmed 
that TGFβ expression was similar for WT and 
MAGP knockout cells.  Cell number was also 
equivalent for all cell types (supporting 
information Fig. S5).  
 
DISCUSSION 
The bioavailability of active TGFβ is tightly 
regulated at multiple levels, both inside and 
outside the cell.  It is a crucial regulator of ECM 
production (24) yet, in turn, is influenced by the 
ECM itself in ways that provide spatiotemporal 
control of growth factor activity (1,25,26).  In the 
ECM, TGFβ family growth factors bind avidly to 
sulfated sugars on proteoglycans as well as to 
ECM proteins (1,26). Fibrillin-containing 
microfibrils are particularly important in 
modulating TGFβ signaling and the mechanisms 
whereby microfibril-associated proteins regulate 
growth factor availability and activity are 
complex.  We and others have shown that the 
fibrillin binding partners MAGP-1 and MAGP-2 
work together with fibrillin to modulate TGFβ 
availability in the ECM (16,27-29).  Mutations in 
MAGP genes lead to phenotypes in mice and 
humans that are associated with abnormal growth 
factor signaling (15,16,18,30-33).  
 The MAGPs are functionally defined by 
the amino acid composition of their front and 
back halves.  The back half of MAGP-1 contains 
13 cysteine residues, the first seven of which 
define the matrix binding domain that mediates 
interactions with fibrillin (34,35).  The matrix 
binding region is the only conserved structural 
motif shared with MAGP-2 and is conserved in 
all species of MAGP-1 and MAGP-2. The 
cysteine-free N-terminal half of MAGP-1 is 
acidic, enriched in proline, and contains tyrosine 
residues that undergo sulfation and threonine 
residues that are sites for O-glycosylation.  
Sequences in this region also mediate 
noncovalent interactions with tropoelastin 
(12,13), the α3 chain of collagen VI (13), decorin 
(36), and biglycan (37).  While secondary 
structure prediction algorithms suggest a random 
configuration for the amino terminal sequences, 
the absence of cysteine residues, the high 
negative charge density, and the binding of 
numerous proteins to this area of the molecule 
suggests a structure that is accessible and 
adaptable.   
 In this report, we used an overlapping 
peptide mapping strategy to localize the growth 
factor-binding domain to 19 amino acids in the N-
terminal region of MAGP-1. The TGFβ binding 
site is contained in domain 4 but requires a part 
of domain 3 for full affinity (Fig. 2). The binding 
sequence is highly acidic due to four aspartic acid 
residues, one glutamic acid, and three tyrosine 
residues that are sites for sulfation (with the 
sulfate group adding more negative charge). The 
acidic residues form a structural repeat, with each 
separated by two nonpolar amino acids. The 
functional significance of this repeating structure 
is not known. The high charge density at this site 
resembles characteristics of heparin, which binds 
TGFβ with high affinity through negatively 
charged sulfated sugars that interact with lysine 
residues on TGFβ (38). In fact, the predicted 
MAGP-1 binding site on TGFβ is the same as that 
postulated for heparin (38,39). While the charged 
residues in MAGP-1 are important for growth 
factor binding, there are conformational and 
flexibility requirements as well, since the 
biologically active p17-35 peptide no longer 
interacts with TGFβ when prolines are inserted to 
introduce structural constraints.  
 MAGP-1 is one of the few matrix proteins 











that binds active TGFβ without the involvement 
of glycosaminoglycans. Some ECM proteins, 
such as fibronectin, thrombospondin, fibulins, 
tenascins, and fibrillins, bind the large latent 
complex form of TGFβ through interaction sites 
on the LTBPs (9,40-43), although several bind 
the active isoform as well. In general, binding 
sites on matrix proteins for active TGFβ are not 
well characterized, but the properties of the 
MAGP-1 growth factor binding domain may be 
instructive for identifying active sequences in 
these as well as other proteins. The microfibrillar 
protein emilin-1, for example, binds specifically 
to the proTGFβ precursor and prevents its 
maturation by furin convertases (44).  Growth 
factor binding activity was mapped to the 
protein’s EMI domain, but the precise sequence 
was not identified nor is it clear whether the 
interaction is with the active or latent regions of 
the growth factor.  Similarly, TGFβ binding 
activity in the matricellular protein SPARC was 
localized in one study to the last 37 amino acids 
in the carboxy-terminal EC domain (45), but 
other work found that SPARC interacted with 
TGFβ only when bound to its cognate type II 
receptor (46). Interestingly, both emilin-1 and 
SPARC have clusters of acidic amino acids in the 
putative TGFβ binding regions that create a 
negatively charged sequence similar to the 
growth factor binding domain in MAGP-1.  
 Our mapping studies create a clearer 
picture of the functionality of the MAGP-1 amino 
terminus.  The first four amino acids in the TGFβ 
binding peptide p17-35 overlap with the last four 
amino acids of a peptide used to define the 
binding site for tropoelastin and collagen VI 
(amino acids 12-21 in our numbering scheme) 
(13). It is not known, however, if TE or collagen 
VI can affect the binding of TGFβ.  Although this 
amino-terminal region seems to be available to 
interact with numerous proteins noncovalently, 
there is a specificity to the binding since MAGP-
1 does not bind TGFβ3, collagens I, II, or V, 
FGF9, FGF21 or the cytokines TNFα, IL-4, IL-
13, and RANKL (13,17).  
 Our finding that MAGP-1 binds active 
TGFβ but not the small latent precursor form of 
the growth factor suggests that MAGP-
containing microfibrils have the potential to store 
active TGFβ in addition to the large latent form 
that covalently binds to fibrillin. Association of 
TGFβ with MAGP-1 does not alter the growth 
factor’s signaling potential, nor does an 
association between MAGP-1 and fibrillin alter 
MAGP-1’s ability to bind TGFβ.  Thus, activated 
TGFβ bound to MAGP-1 on microfibrils is 
capable of signaling when interacting with its 
receptor on cells and does not require an 
additional activation step to do so.   
 It is noteworthy that the absence of MAGP-
1 or MAGP-2 (or both) is sufficient to raise the 
amount of total TGFβ stored in the ECM of 
cultured cells. This finding is consistent with 
studies by Massam-Wu et al. (23), who showed 
the MAGP-1 could directly compete with LTBP-
1 for binding to fibrillin. In the absence of 
MAGP, one would, therefore, expect more total 
TGFβ to be associated with the ECM, which is 
what we found using MAGP knockout cells. 
Importantly, the presence of latent but not active 
TGFβ in the ECM of MAGP-1:MAGP-2 double 
knockout cells suggests that in the absence of the 
MAGPs, active TGFβ is not retained in the 
matrix.  
 The mechanistic and functional mapping 
studies described in this report, together with our 
previous characterization of MAGP knockout 
mouse phenotypes indicating increased TGFβ 
activity, provide strong evidence for regulation of 
the TGFβ pathway as one of MAGP’s major 




Materials:   
 Carrier-free active TGFβ-1 (7666-MB-
CF), BMP-2 (355-BM-010/CF) and latent TGFβ-
1 (299-LT) were purchased from R&D systems, 
Minneapolis, MN. Antibodies to MAGP-1 and 
fibrillin-2 have been described (36,47,48).  
Simply Blue Coomassie G-250 was obtained 
from Thermo Fisher scientific. Antibodies to 
Smad2/3 (5678S) and phospho-Smad2 (18338S) 
were from Cell Signaling, Danvers, MA. 
 
Cell culture and TGFβ-1 activity assay:   
 The TGFβ reporter cell line MFB-F11 was 
a generous gift from Tony Wyss-Coray, Stanford 
University. The cells were routinely cultured in 
DMEM supplemented with non-essential amino 
acid, 10% fetal calf serum, and 100µg/ml 











hygromycin B (Invitrogen, Carlsbad CA).  On the 
afternoon before an assay, the cells were split into 
a 96 well assay plate (4 x 104 cells per well) and 
cultured overnight in the absence of hygromycin.  
For the assay, cells were rinsed in DMEM then 
incubated for 1 hour in DMEM-BSA (DMEM + 
1.0 mg/ml heat-denatured BSA).  To determine if 
MAGP-1 or the p17-35 peptide inhibits TGFβ 
signaling, TGFβ (80pM) was mixed with varying 
concentrations of MAGP-1 protein or p17-35 
peptide in DMEM-BSA for 30 minutes at room 
temperature then incubated with the reporter cells 
for 24 h.  Soluble alkaline phosphatase released 
into the media in response to TGFβ was measured 
using the Phospha-Light™ SEAP Reporter Gene 
Assay System (Life Technologies).  
 
MEF and MFB-F11 co-culture  
 Levels of active and total TGFβ in the ECM 
of cultured MEFs were assessed using established 
methods (20,49).  Embryonic fibroblasts from 
wild type and MAGP-1 knockout mice were 
generated from explants as previously described 
(18).  Early passage cells (passage 4 or less) were 
maintained in DMEM with 10% fetal calf serum 
supplemented with non-essential amino acids and 
routinely passaged 1:3 at confluence.  For growth 
factor measurements, cells were plated at 
confluence in replicate 12 well tissue culture 
dishes and maintained for 14 days prior to TGFβ 
assays.  The cells were rinsed with PBS and 
incubated for 1 hr in DMEM containing 1 mg/ml 
of heat denatured BSA. For measurement of 
active TGFβ levels, approximately 1x105 MFB-
F11 reporter cells in DMEM-heat denatured BSA 
were added to the cultured MEF cells and 
incubated overnight.  Supernatant from this co-
culture was assayed for alkaline phosphatase 
using the Phospha-Light™ SEAP Reporter Gene 
Assay System (Life Technologies).   
 To determine total protein and total TGFβ, 
MEF cells were rinsed with PBS and the cell layer 
incubated in 250 µl 0.2M HCl per well for 1 hour 
on ice.  An aliquot was removed for total protein 
determination and the remaining solution 
neutralized by the addition of an equimolar 
amount of NaOH.  The cell-layer extract was 
diluted 1:100 in DMEM containing 1mg/ml heat 
denatured BSA and assayed for TGFβ using 
MFB-F11 cells as described above.  The samples 
taken for protein determination were dried, 
hydrolyzed in 6N HCl for 48 hours, and amine 
content measured with ninhydrin (50). 
 
Smad2 phosphorylation:   
 RFL-6 cells were plated at a confluent 
density and incubated overnight in Ham’s F12 
medium containing 0.5% horse serum followed 
by a 1-hour incubation with Ham’s F12 
containing 0.1mg/ml heat denatured BSA to 
decrease background TGFβ activity.  TGFβ-1 
(50pM) was mixed with 0, 0.4, 20, or 1000nM 
MAGP-1 in Ham’s F12 containing 0.1mg/ml heat 
denatured BSA for 1 hour at 37°C then added to 
the RFL-6 cells for 15 minutes.  Cells were lysed 
in buffer containing 20mM Tris, pH 7.5, 
150mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
Triton X-100, 2.5mM sodium pyrophosphate, 
1mM β-glycerophosphate, 1mM Na3VO4, 
1mM NaF 1× protease inhibitor (Roche Applied 
Science). Lysates were cleared by centrifugation, 
and protein concentration determined.  Eight µg 
of lysate was run per lane on 10% SDS-PAGE 
gels then transferred to nitrocellulose 
membranes.  Membranes were blocked in 1% 
casein then incubated overnight with the 
indicated primary antibodies. Antibodies were 
detected with secondary antibodies conjugated to 
horse radish peroxidase and visualized using 
chemiluminescent substrate (Millipore 
WBKLS0100). The standards used were 
Precision Plus Dual Color protein standards 
(Biorad 161-0374) 
 
MAGP-1 recombinant expression constructs:   
 Mouse MAGP-1 cDNA was amplified 
from a full-length clone (IMAGE:5249342) using 
a forward primer with a SphI restriction site 
added to the 5’end (full-length forward primer 
with Sph1) and a reverse primer with SacI 
restriction site added to 3’ end (full-length 
reverse primer with SacI).  The resultant 
amplification product along with pQE31 was 
digested with SphI and SacI, gel purified, and 
appropriate bands ligated.   The ligation mix was 
used to transform the M15 strain of E-coli, and a 
bacterial colony containing a plasmid with the 
appropriate sequence was used for expression.   
 A fragment of MAGP-1 representing 
domains 3-4 was amplified from the full-length 
pQE31 construct using a forward primer 
(truncation forward) from pQE31 sequence and a 











reverse primer from the MAGP-1 sequence 
containing a SacI restriction site (Exon 4 reverse 
with SacI).  The amplification product, along 
with pQE31 was digested with EcoRI and SacI, 
gel purified, and appropriate bands extracted and 
ligated. Fragments for domain 4-9 and 5-9 
truncations were amplified from the full-length 
construct using a reverse primer from pQE31 
(truncation reverse) sequence and a forward 
primer from MAGP-1 sequence containing a 
BamHI restriction site (exon 4 forward with 
BamH1 or exon 5 forward with BamHI).  The 
amplification products were digested along with 
pQE31 with BamHI and SacI, gel purified, and 
the appropriate bands ligated.  The ligation mix 
from each construct was used to transform M15 
E. coli. Colonies were picked from the 
transformations and sequence verified. The 
primer sequences used to construct 6-His full-
length and truncated MAGP-1 are:   
Full-length forward primer with Sph1: 
TAGCATGCTCAGGGCCAATATGACCTGG
A,  





Exon 4 reverse with SacI:  
CAGAGCTCTCTTGGTAGTCATAGTAGTCT
G  
Exon 4 forward with BamH1 
CAGGATCCTGACAACGCAGACTACTATG 





Peptides, protein expression and purification: 
 6-His-tagged fusion proteins were 
expressed and purified using the Qiagen 
expression system (Qiagen Inc. Valencia, CA).  
Bacteria expressing full-length or truncated 
protein were expanded, and while in log-phase, 
induced with IPTG at 1mM final concentration 
for 4 hours at 30oC.  The bacteria were collected 
by centrifugation, extracted overnight at 4oC with 
gentle agitation in TRIS-phosphate buffered urea 
(8M pH8.0) containing protease inhibitors.  After 
clarifying the extract by centrifugation (12,000xg 
for 20 minutes), recombinant 6-His containing 
proteins were isolated with nickel resin 
chromatography.  Proteins were refolded on the 
column (51), and eluted with a 0-300mM 
imidazole gradient in 50mM TRIS pH7.4.  
Fractions were analyzed by SDS-PAGE, and 
fractions containing protein were dialyzed 
against water and lyophilized.  The fusion-
proteins were further purified using HPLC over a 
PRP-3 reverse-phase column using a 0-30% 
acetonitrile gradient in 0.05% triethylamine.  The 
protein content of purified proteins was 
determined by absorbance at 280nm using an 
extinction coefficient based on the protein 
sequence (DNAstar, Madison WI).  The purity of 
the expressed proteins was assessed using SDS-
PAGE with reducing (10mM DTT) sample buffer 
on 8-25% gradient Phastgels (GE Healthcare Life 
Sciences Pittsburgh, PA) and stained with Simply 
Blue (Invitrogen).  Peptides were synthesized by 
Genscript (Piscataway, NJ) and further purified 
using HPLC over a PRP-3 reverse-phase column 
using a 0-30% acetonitrile gradient in 0.05% 
triethylamine.  Fractions were dried and analyzed 
by amino acid analysis. 
 
RNA isolation and quantitative PCR: 
 RNA was isolated using a RNeasy kit 
(Qiagen74104) after cell homogenization using 
QIAshredder (Qiagen 79656). cDNA was 
generated using the high capacity RNA-to-cDNA 
kit (Applied Biosystems 4387406).  Quantitative 
PCR was performed on a ViiA7 (Applied 
Biosystems) using reagents and taqman probes 
supplied by Applied Biosystems for GAPDH 
(Mm99999915G1) and TGFβ 
(Mm01178820_m1). Quadruplicate 
measurements from 100ng RNA were performed 
for each sample. 
 
Purification of Fibrillin-2 
 Fifty ml of serum-free conditioned medium 
from SF-9 cells expressing full-length fibrillin-2 
(manuscript in preparation) was applied at a flow 
rate of 4ml/min onto a 1.0 x 9.5 cm Source 15Q 
strong anion exchange column (GE Healthcare) 
at room temperature using a Pharmacia FPLC 
system.  The column was washed with 50ml 
buffer A (buffer A:  25mM HEPES, 0.1mM 
CaCl2 pH7.4) followed by a 10ml gradient from 
0-25% buffer B (buffer B:  25mM HEPES, 
0.1mM CaCl2, 1.0M NaCl pH7.4).  Fibrillin-2, 











which remained bound to the resin, was eluted 
with a 50ml 25-50% linear buffer B gradient 
before the column was recycled with 15ml 100% 
buffer B and 100ml buffer A. The elution stream 
was monitored for protein at 228 nm and NaCl 
content using conductivity. Each fraction was 
assessed for fibrillin-2 using an antifibrillin-2 
antibody via dot-blot and densitometry with 
ImageJ.  The three peak fractions containing 
fibrillin-2 were pooled and further purified on a 
1.6 cm x 1.6 m Sephacryl S-500 column 
(fractionation range 40 - 20,000 KDa) 
equilibrated in 25mM HEPES, 125mM NaCl 
0.1mM CaCl2 pH7.4.  The column flow rate was 
1ml/min at 4˚C, and 6ml fractions were collected. 
The elution stream was monitored for protein at 
280nm and fibrillin-2 content for each fraction 
was determined by dot-blot. The final product 
was analyzed by SDS-PAGE on a 4% 
polyacrylamide gel with Laemmli buffer in the 
presence and absence of a reducing agent.  
Duplicate gels were either stained with Simply 
Blue Coomassie G-250 or transferred to 
nitrocellulose and stained for fibrillin-2 by 
western blot.  The purity of the fibrillin-2 is 
shown in supplemental figure 3.  The standards 
used were Precision plus dual color protein 
standards (Bio-Rad inc.).  The western blot 
detection used a secondary donkey anti-rabbit 
antibody-HRP conjugate (Amersham Inc.) that 
was visualized on film using a chemiluminescent 
substrate (Millipore Corporation).   
 
Surface plasmon resonance: 
 Initial mapping of the TGFβ-1 binding site 
in MAGP-1 was accomplished using a Biacore X 
to measure the change in surface plasmon 
resonance due to the interaction of TGFβ-1 in 
solution with expressed full-length MAGP-1 or 
truncated MAGP-1 fragments coupled to a CM5 
chip.  For coupling, the protein was dissolved at 
20 µg/ml in 5mM acetate buffer, pH4.5, and 
injected for 10 minutes onto a CM5 sensor chip 
previously activated for 10 minutes with 0.05M 
NHS-0.2M EDC.  Reactive sites on the chip were 
quenched with 100ul of 100mM ethanolamine 
pH=8.0 then the chip was equilibrated in HBST 
running buffer (10mM HEPES 150mM NaCl 
pH=7.4 containing .01% triton-100).  Varying 
concentrations of TGFβ-1 diluted in running 
buffer were then injected.   The volume of TGFβ-
1 injected was 60ul, and the flow rate was 
20ul/minute.  The precise localization of the 
growth factor binding site in MAGP-1 was 
determined using inhibition of TGFβ-1 binding to 
full-length MAGP-1 by synthetic peptides.  
These experiments and the latent TGFB binding 
studies were performed on a Reichert SR7000DC 
SPR system.  Full-length MAGP-1 was coupled 
to a carboxymethyl dextran hydrogel surface 
sensor chip using the same coupling conditions 
used for the Biacore CM-5 chip.  TGFβ-1 or 
BMP-2 (50nM final concentration) was mixed 
with varying concentrations of MAGP-1 
synthetic peptide at room temperature for at least 
15 minutes prior to injection.   The flow rate for 
the localization studies was 50 µl/minute, and the 
injection volume was 100ul.    
 Latent TGFβ-1 (5uM stock solution) was 
diluted to 15nM in HBST and injected over the 
MAGP-1 chip.  To activate the latent TGFβ-1, 
HCl was added to the latent TGFβ-1 stock 
solution to a final concentration of 100mM for 15 
minutes at room temperature followed by 
neutralization with the addition of an equimolar 
concentration of NaOH. The activated TGFβ-1 
was diluted to 15nM in HBST and injected over 
the full-length MAGP-1 chip.  
 In ternary complex studies, fibrillin-2 was 
diluted 1:5 in 5mM sodium acetate and coupled 
with repeat 250ul injections onto a CM-5 
activated and blocked as described above.  
Approximately 4000uRIU were coupled to the 
chip.  Direct binding of TGFβ-1 and BMP-2 to 
fibrillin-2 was initially assessed prior to loading 
MAGP-1 onto the fibrillin-2 chip.  After direct 
binding experiments, the chip was recycled, and 
MAGP-1 was loaded onto the chip with duplicate 
MAGP-1 injections (100ul injection at 500nM) 
where approximately 130uRU bound.  Binding of 
TGFβ-1 and BMP-2 to the complex of fibrillin-2 
and MAGP-1 was then re-assessed.  No recycling 
was performed between injections on the 
fibrillin-2 MAGP-1 complex.  HBST was used as 
the sample dilution buffer as the mobile phase.  
Unless otherwise noted, chips were recycled with 
50ul injections of 0.2M glycine pH=2.3.   
 
MAGP peptide structure prediction 
 The MAGP-1 p17-35 region that was 
experimentally determined to bind to TGFβ was 
analyzed for potential secondary structure and 











disorder.  Secondary structure was predicted 
using Jpred4 (52), Psipred (53), and DISOPRED 
(54).  Additionally, the sequence was analyzed 
using IUPred2A (55).  Structural predictions 
were performed using PEP-FOLD and PEP-
FOLD3 (56,57) 
 
MAGP-TGFβ interaction predictions 
 TGFβ family structures were downloaded 
from the protein data bank 1TGK (58), 4KV5 
(59), 1KLA, 1KLC, 1KLD (60).  Structures were 
edited to delete any additional ligands or binding 
partners.  When appropriate, structures were 
subjected to energy minimization in NAMD (61) 
to produce a relaxed structure.  Based on 
experimental SPR results from the lab, the 
MAGP-1 p17-35 sequence were chosen as 
docking candidates.  The sequences were treated 
as flexible peptides and were docked to the TGFβ 
structures using GalaxyDock (62) and CABS-
dock (63).  Predicted structures were evaluated by 
score and feasibility.  Structures were manually 
compared to structures of known TGFβ-
containing complexes, specifically receptor 
bound TGFβ 3KFD (64) and TGFβ in the large 
latent complex 3RJR (65), 5VQP (66).  Structures 
were visualized using VMD (67) and VMD was 
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Figure 1. Domain structure of MAGP-1 and purity of expressed peptides.  A) Full-length, secreted, 
MAGP-1 protein is encoded by seven exons (exons 3-9).  In this report, each exon defines a protein 
domain, and truncations used for functional analysis were constructed based on exon boundaries. The 
schematic shows the domains included in the recombinant fragments (d followed by exon numbers).  B) 
SDS-PAGE analysis of recombinant full-length MAGP-1 (FL) and purified truncated peptides shown in 
panel A.  Proteins were separated on 8-25% Phastgels under reducing conditions and detected with 
Coomassie Brilliant Blue.  The observed and expected molecular weights of each fragment are described 
in the Results section. 
 
  















Figure 2. Binding of TGFβ-1 to purified full-length MAGP-1 or MAGP-1 fragments. 
A) Graph of isotherms from the binding of TGFβ-1 to a CM5 chip coated with full-length MAGP-1 (2200 
resonance units coupled).  TGFβ-1 concentrations were, from the top, 100, 66.7, 44.4, 29.6, 19.8, 13.2, 
8.8, 5.9, 3.9, 2.6, and 1.7 nM. B-D) show the interaction of TGFβ-1 (400, 200, 80, 67, 27 nM) with 440 
resonance units of MAGP-1 domain protein 3-4 (B), with 4300 resonance units of MAGP-1 domain 4-9 
(TGFβ-1 concentrations of 120, 60, 48, 24,12 nM) (C), and 400nM TGFβ-1 with 2140 resonance units of 

































































Figure 3. Fine mapping of TGFβ-1 binding activity in domains 3-4.  A) summarizes the inhibitory 
activity, the sequence and the location of the peptides tested for inhibition of TGFβ-1 (50nM) binding to 
120 units of full-length MAGP-1 coupled to a carboxymethyl dextran hydrogel surface sensor chip 
(MAGP-1 chip). B) is a graph of isotherms showing p17-35 dose-dependent inhibition of TGFβ-1 binding 
to the MAGP-1-coated chip. C) relates the maximal binding of TGFβ-1 (at 100 seconds) to the MAGP-1 
chip in the presence of increasing concentrations of peptide p17-35 (taken from panel B). Isotherms in D) 
show that the control peptide p17-35pro (100, 50, 25 and 0 µM) has no inhibitory effect on TGFβ-1 
binding to MAGP-1.   
 
  















Figure 4.  MAGP-1 does not bind latent TGFβ-1.  Latent TGFβ-1 (15nM) was injected onto a MAGP-
1 chip, and no interaction was detected.  A second sample of latent TGFβ-1 was treated with 100mM HCl 
for 10 minutes at room temperature, neutralized with 100mM NaOH, and then diluted to a final 
concentration of 15nM.  The binding isotherm shows that the acid-activated TGFβ-1 bound with high 
affinity to the MAGP-1 chip.  The injection volume was 225 µl, and the flow rate was 50 µl/minute for 
both injections.  
 
  















Figure 5. MAGP-1 and p17-35 do not block TGFβ-1 signaling.  A)  Active TGFβ-1 (80pM) was 
mixed with the indicated concentrations of MAGP-1, incubated for 15 minutes, and then added to MFB-
F11 cells for 24 hours.  The culture medium was then assayed for alkaline phosphatase activity, which 
provides a measure of TGFβ activity. Shown are mean +/- standard deviation, n=8.  B) Active TGFβ-1 
(80pM) was mixed with 10µM or 100µM p17-35, p17-35pro, or no peptide for 15 minutes and added to 
MFB-F11 cells for 24 hours. A control with no added TGFβ-1 was included.  The medium was collected 
and assayed for alkaline phosphatase activity.  Shown are mean +/- standard deviation, n=4.  One-way 
analysis of variance showed no differences between samples in panels A or B.  C)  Increasing 
concentrations of soluble MAGP-1 were pre-incubated for 1 hour with 50pM TGFβ-1 and the complex 
incubated with RFL-6 cell (a fibroblast line that does not make MAGP-1) for 15 minutes.  Cell extracts 
were then analyzed by western blot for phosphoSmad2 (pSmad-2) (top) and for total Smad2 (tSmad2) 
(bottom).  The ratio of pSmad2 to tSmad2 is shown in the bottom graph.  D)  Smad2 phosphorylation in 
RFL-6 cells is TGFB-1 dose dependent with minimal baseline phosphorylation.  RFL-6 cells were treated 
with the indicated dose of TGFβ-1 and levels of phosphorylated Smad-2 (top panel) or total Smad-2 
(bottom panel) were determined from cell extracts by western blot analysis.  The ratio of pSmad2 to 
tSmad2 is shown in the bottom graph.  
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Figure 6:  The structure of TGFβ-1with and without the MAGP-1 p17-35 peptide. Top: Side and top 
views of the TGFβ-1 dimer with solvent exposed residues R94, K95, and K97 shown in green.  Bottom: 
Representative binding of the MAGP-1 p17-35 peptide (shown in black) to TGFβ-1.  The MAGP-1 
peptide remains largely disordered while consistently interacting with the positive residues in the TGFβ-1 
finger region. 
  

















Figure 7.  TGFβ-1 binds to fibrillin-2 only in the presence of MAGP-1.  A) Purified full-length 
fibrillin-2 was covalently coupled (3,000 resonance-units) to a carboxymethyl dextran hydrogel surface 
sensor chip (fibrillin-2 chip), and TGFβ-1 was injected at a concentration of 50nM at 25ul per minute for 
3.5 minutes. Data show no measurable interaction between the two proteins.  B)  MAGP-1 (6.2nM for 3.5 
minutes at 25µl/min) bound to fibrillin-2 with an apparent affinity of 100pM.   C)  TGFβ-1 (50nM for 3.5 
minutes at 25ul/min) bound to the MAGP-1-fibrillin-2 complex whereas TGFβ-1 pre-incubated with 
50µM p17-35 peptide failed to bind to the complex.  
 
  














Figure 8.  BMP-2 binding localizes to the same domain on MAGP-1 as TGFβ-1.  A) shows isotherms 
documenting binding of 50nM BMP-2 to a MAGP-1-coated chip.  B) Binding was inhibited by 
preincubation of BMP-2 with peptide p17-35 from the top 0, 5, 25, and 50uM) but not the control peptide 
















































Figure 9.  MAGP 1 and MAGP-2 modulate TGFB levels in fibroblast ECM.  Comparison of total TGFβ 
levels (black bars) in 14 day post confluent WT and MAGP knockout cell layers showing significant increases 
in total TGFβ in MAGP-1 knockout (**p>0.01, n=3), MAGP-2 knockout (*p> 0.05, n=3), and MAGP-
1;MAGP-2 double knockout (** p>0.01) fibroblasts. Similarly, active TGFβ levels (grey bars) are significantly 
increased in MAGP-1 knockout (* p>.05, n=2) and MAGP-2 knockout (* p>.05, n=3) cells, but are decreased 
(** P>.01 n=3) in the double knockouts. 
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